<a href="https://www.fiercebiotech.com/biotech/enterprise-reports-phase-2-cystic-fibrosis-win-succeeding-where-big-pharma-stumbled" hreflang="en">Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled</a>
fiercebiotech.com·May 11, 2026
Enterprise Therapeutics' cystic fibrosis drug candidate has successfully met its primary endpoint in a phase 2 trial, advancing the company's efforts in a field previously explored by other firms like Vertex.
The successful phase 2 trial of Enterprise Therapeutics' cystic fibrosis drug candidate indicates a promising opportunity in targeting areas previously explored by industry leaders like Vertex. For someone tracking biotech and drug discovery, this development suggests potential investment opportunities or strategic partnerships, as the drug progresses towards further clinical trials and potential market entry.